Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1967]
News [3164]
Articles [130]
Editorials [3]
Conferences [121]
elearning [17]
TKI cessation for CML patients with deep molecular response: an update from the...
Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016
Tailoring therapy for leukaemia patients
Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA
Tailoring therapy for leukaemia patients ( Dr Mikkael Sekeres - Cleveland Clinic, Cleveland, USA )
3 Dec 2016
Dose reduction of TKIs for CML patients with deep molecular response
Prof Mhairi Copland - University of Glasgow, Glasgow, UK
Dose reduction of TKIs for CML patients with deep molecular response ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016
Updates from the EURO-SKI trial of tyrosine kinase cessation
Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France
Updates from the EURO-SKI trial of tyrosine kinase cessation ( Dr Francois-Xavier Mahon - Université Bordeaux, Bordeaux, France )
3 Dec 2016
Incidence and risk factors for central venous catheter related thrombosis in...
Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA
Incidence and risk factors for central venous catheter related thrombosis in children ( Dr Julie Jaffray - Children's Center for Cancer, Los Angeles, USA )
3 Dec 2016
CML patients with stable response may safely decrease dose of TKI
Prof Mhairi Copland - University of Glasgow, Glasgow, UK
CML patients with stable response may safely decrease dose of TKI ( Prof Mhairi Copland - University of Glasgow, Glasgow, UK )
3 Dec 2016
Vadastuximab talirine in combination for newly diagnosed AML
Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Vadastuximab talirine in combination for newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016
Novel antibody boosts responses in newly diagnosed AML
Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA
Novel antibody boosts responses in newly diagnosed AML ( Prof Harry Erba - UAB Comprehensive Cancer Center, Birmingham, USA )
3 Dec 2016
Anti CD22 CAR T cell therapy for relapsed paediatric ALL
Dr Nirali Shah - National Cancer Institute, Bethesda, USA
Anti CD22 CAR T cell therapy for relapsed paediatric ALL ( Dr Nirali Shah - National Cancer Institute, Bethesda, USA )
3 Dec 2016
A new spin on leukaemia therapy
Prof Armand Keating - University of Toronto, Toronto, Canada
A new spin on leukaemia therapy ( Prof Armand Keating - University of Toronto, Toronto, Canada )
3 Dec 2016
Subgroup analysis of elderly high risk AML patients receiving CPX-351
Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA
Subgroup analysis of elderly high risk AML patients receiving CPX-351 ( Prof Jeffery Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )
3 Dec 2016
Remissions following anti-CD22 CAR therapy in children with relapsed ALL
Dr Terry Fry - National Cancer Institute, Bethesda, USA
Remissions following anti-CD22 CAR therapy in children with relapsed ALL ( Dr Terry Fry - National Cancer Institute, Bethesda, USA )
3 Dec 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation